التفاصيل البيبلوغرافية
| العنوان: |
Persistence with IDegLira in Patients in Clinical Practice: A Nationwide Observational Study in Sweden. |
| المؤلفون: |
Eliasson, Björn1,2 (AUTHOR) bjorn.eliasson@gu.se, Ekelund, Jan3 (AUTHOR), Miftaraj, Mervete3 (AUTHOR), Ranthe, Mattis Flyvholm4 (AUTHOR), Mårdby, Ann-Charlotte5,6 (AUTHOR), Da Rocha Fernandes, João Diogo4 (AUTHOR), Svensson, Ann-Marie1,2 (AUTHOR) |
| المصدر: |
Diabetes Therapy. Aug2020, Vol. 11 Issue 8, p1807-1820. 14p. |
| مصطلحات موضوعية: |
*GLUCAGON-like peptide-1 receptor, *GLYCEMIC control, *GLUCAGON-like peptide-1 agonists, *REGULATION of body weight, *TYPE 2 diabetes |
| مصطلحات جغرافية: |
SWEDEN |
| مستخلص: |
Aims: To explore persistence with insulin degludec/liraglutide (IDegLira) treatment, clinical characteristics and concomitant medications in a large population of patients in clinical practice. Methods: This was an observational study in patients with type 2 diabetes (n = 2432) who initiated IDegLira between 26 May 2015 and 31 December 2017. Data were obtained from Swedish nationwide registers and linked on an individual level using unique Swedish personal identifiers. Dose calculations were made for patients with ≥ 180 days between the first and last collections of IDegLira prescription. Changes in clinical parameters were evaluated as change from the last observation during 12 months prior to the initiation date until ± 90 days from the last collection of IDegLira. Results: Pre-index regimens (index date being the date of filling the first prescription of IDegLira) included: multiple daily insulin injections (45.1%); insulin and glucagon-like peptide-1 receptor agonist (GLP-1 RA) (19.7%); long-acting insulins (11.8%); non-injectable therapy only (11.4%); GLP-1 RA only (9.8%); and no collection of diabetes medication during the 6-month pre-index period (2.3%). The majority of patients (94 and 84%) were persistent with IDegLira at 6 and 12 months, respectively. The most commonly used concomitant medication was metformin (69.4%). Mean daily dose was 33 dose steps. Overall, there was a mean decrease in HbA1c (approx. 10 mmol/mol [1%]) and body weight (− 1.1 kg). Improvements in HbA1c were observed regardless of pre-index treatment. Conclusion: After 12 months, 84% of patients were persistent on IDegLira, with improved glycaemic control and reductions in body weight. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
Full Text Finder